Cotreatment of K562 cells and primary CML samples led to caspase-3 activation and HtrA2/Omi-mediated decreased XIAP levels both in K562 cells and TKI-insensitive CML hematopoietic progenitors [123]. The gene discussed is XIAP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.